Medical Cannabis: a crucial step towards a French ecosystem

Pharmaceutical companies qualified to manufacture either active substances or medicines will now be able to produce cannabis-based medicines in France.

A look back at some of 2021’s key highlights at StaniPharm

Manufacturing of clinical GMP batches of a new vaccine adjuvant, development of innovative cannabis-based medicines ...

Vaxinano partners with StaniPharm for development and production of its vaccine delivery system

"Scaling up this kind of vaccine delivery system is a crucial step and requires a strong partner" says Dr. Didier Betbeder, CEO of Vaxinano.

Developing a French “patient to seed” ecosystem to improve the therapeutic benefit of medical Cannabis

"Simply replacing the imported products currently specified for the pilot program with French-produced equivalents would be a missed opportunity and a disservice to patients"

Cybernano and StaniPharm join forces to develop tomorrow’s health products

The complementary nature of their expertise and technologies will provide complete support for start-ups and SMEs from development through clinical trials.

Drug nanoparticles – a common approach to tackle the poor aqueous solubility of APIs

Nanosizing drug particles brings key benefits for oral formulations of poorly soluble drugs such as Biopharmaceutics Classification System (BCS) Class II drugs.

8 supercritical companies inspired by Michel Perrut, founder of SEPAREX

SEPAREX, the gold standard in supercritical fluids, was founded in 1985 by Michel Perrut. SEPAREX was also a pioneering business incubator, far ahead of its time, contributing to the birth of 8 companies.